Cancer Letters · 2020 · 29 citations · 41 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCytotoxic T Lymphocyte ResponsesImmune Checkpoint RegulationT Cell ExhaustionT Cell Responses To TumorsCd8 Positive T CellsCd8 T Cell ActivationCd8+ Tumor-infiltrating LymphocytesPd-l1 BlockadeProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Death-1 InhibitionProgrammed Death-ligand 1 Signaling
41
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text